Literature DB >> 4576891

Drugs and lipid metabolism.

R J Havel, J P Kane.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1973        PMID: 4576891     DOI: 10.1146/annurev.pa.13.040173.001443

Source DB:  PubMed          Journal:  Annu Rev Pharmacol        ISSN: 0066-4251            Impact factor:   13.820


× No keyword cloud information.
  12 in total

1.  Effect of clofibrate on brain mevalonate-5-pyrophosphate decarboxylase.

Authors:  M F Zafra; S Riquelme; M Castillo; E Garcia-Peregrin
Journal:  Neurochem Res       Date:  1987-09       Impact factor: 3.996

2.  Inhibition of hormone-stimulated lipolysis by clofibrate. A possible mechanism for its hypolipidemic action.

Authors:  M A D'Costa; A Angel
Journal:  J Clin Invest       Date:  1975-01       Impact factor: 14.808

Review 3.  Lowering cholesterol, 1988. Rationale, mechanisms, and means.

Authors:  R J Havel
Journal:  J Clin Invest       Date:  1988-06       Impact factor: 14.808

4.  The effects of clofibrate on plasma glucose, lipoproteins, fibrinogen, and other biochemical and haematological variables in patients with mature onset diabetes mellitus.

Authors:  G D Calvert; L Blight; J Franklin; J Oliver; P Wise; A S Gallus
Journal:  Eur J Clin Pharmacol       Date:  1980-05       Impact factor: 2.953

5.  Studies on the mechanism of action of halofenate.

Authors:  L R Mandel
Journal:  Lipids       Date:  1977-01       Impact factor: 1.880

6.  Paradoxical effects of clofibrate on liver and muscle metabolism in rats. Induction of myotonia and alteration of fatty acid and glucose oxidation.

Authors:  H S Paul; S A Adibi
Journal:  J Clin Invest       Date:  1979-08       Impact factor: 14.808

7.  Effect of neonatal modulation of cholesterol homeostasis on subsequent response to cholesterol challenge in adult guinea pig.

Authors:  J R Li; L K Bale; B A Kottke
Journal:  J Clin Invest       Date:  1980-05       Impact factor: 14.808

8.  Clofibrate and diabetes control in patients treated with oral hypoglycaemic agents.

Authors:  J C Daubresse; D Daigneux; M Bruwier; A Luyckx; P J Lefebvre
Journal:  Br J Clin Pharmacol       Date:  1979-06       Impact factor: 4.335

9.  Eicosapentaenoic acid at hypotriglyceridemic dose enhances the hepatic antioxidant defense in mice.

Authors:  A Demoz; N Willumsen; R K Berge
Journal:  Lipids       Date:  1992-12       Impact factor: 1.880

10.  Hypolipidemic effects of clofibrate and selected chroman analogs in fasted rats: II. High sucrose-fed animals.

Authors:  A Mukhopadhyay; S T Patel; M O'Brien; S S Kokrady; H A Newman; D T Witiak; R R Lanese; J C Rice; D R Feller
Journal:  Lipids       Date:  1983-01       Impact factor: 1.880

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.